Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum

被引:5
作者
Goossens, Julie [1 ]
Cervantes Gonzalez, Alba [2 ,3 ,4 ]
Dewit, Nele [5 ]
Lidon, Laia [2 ,3 ,4 ]
Fortea, Juan [2 ,3 ,4 ]
Alcolea, Daniel [2 ,3 ,4 ]
Lleo, Alberto [2 ,3 ,4 ]
Belbin, Olivia [2 ,3 ,4 ]
Vanmechelen, Eugeen [1 ]
机构
[1] ADx Neuro Sci NV, Ghent, Belgium
[2] Univ Autonoma Barcelona, Hosp St Creu & St Pau, Neurol Dept, St Pau Memory Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, IB St Pau, Barcelona, Spain
[4] Network Ctr Biomed Res Neurodegenerat Dis CIBERNE, Madrid, Spain
[5] Flow Cytometry Unit, Medpace Reference Labs AA, Louvain, Belgium
关键词
VAMP-2; SNAP-25; Neurogranin; Alzheimer's disease; Synapse; Cerebrospinal fluid; Biomarker; Cognitive domains; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; PATHOLOGY; PROGRESSION; BIOMARKERS; CORRELATE; NEUROPIL; REVEALS; DECLINE;
D O I
10.1186/s13195-023-01336-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer's disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related synapse degeneration in cerebrospinal fluid (CSF). The aim of this study was to explore the CSF profile of VAMP-2 across the AD continuum in relation to core AD biomarkers, other synaptic proteins, neurogranin (Ng) and synaptosomal-associated Protein-25 kDa (SNAP-25) and cognitive performance.Methods We developed a digital immunoassay on the Single Molecule Array platform to quantify VAMP-2 in CSF and used existing immunoassays to quantify Ng, SNAP-25 and core CSF AD biomarkers. The clinical study included 62 cognitively unimpaired AD biomarker-negative subjects and 152 participants across the AD continuum from the SPIN cohort (Sant Pau Initiative on Neurodegeneration). Cognitive measures of episodic, semantic, executive and visuospatial domains and global cognition were included. Statistical methods included chi(2) tests, spearman correlation, and ANCOVA analyses.Results The VAMP-2 assay had a good analytical performance (repeatability 8.9%, intermediate precision 10.3%). Assay antibodies detected native VAMP-2 protein in human brain homogenates. CSF concentrations of VAMP-2, neurogranin and SNAP-25 were lower in preclinical AD stage 1 compared to controls and higher at later AD stages compared to AD stage 1 and were associated with core AD biomarkers, particularly total tau (adj. r(2 )= 0.62 to 0.78, p < 0.001). All three synaptic proteins were associated with all cognitive domains in individuals on the AD continuum (adj. r(2) = 0.04 to 0.19, p < 0.05).Conclusions Our novel digital immunoassay accurately measures VAMP-2 changes in CSF, which reflect AD biomarkers and cognitive performance across multiple domains.
引用
收藏
页数:13
相关论文
共 55 条
  • [1] The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
    Alcolea, Daniel
    Clarimon, Jordi
    Carmona-Iragui, Maria
    Illan-Gala, Ignacio
    Morenas-Rodriguez, Estrella
    Barroeta, Isabel
    Ribosa-Nogue, Roser
    Sala, Isabel
    Sanchez-Saudinos, M. Belen
    Videla, Laura
    Subirana, Andrea
    Benejam, Bessy
    Valldeneu, Silvia
    Fernandez, Susana
    Estelles, Teresa
    Altuna, Miren
    Santos-Santos, Miguel
    Garcia-Losada, Lidia
    Bejanin, Alexandre
    Pegueroles, Jordi
    Montal, Victor
    Vilaplana, Eduard
    Belbin, Olivia
    Dols-Icardo, Oriol
    Sirisi, Sonia
    Querol-Vilaseca, Marta
    Cervera-Carles, Laura
    Munoz, Laia
    Nunez, Raul
    Torres, Soraya
    Camacho, M. Valle
    Carrio, Ignasi
    Gimenez, Sandra
    Delaby, Constance
    Rojas-Garcia, Ricard
    Turon-Sans, Janina
    Pagonabarraga, Javier
    Jimenez, Amanda
    Blesa, Rafael
    Fortea, Juan
    Lleo, Alberto
    [J]. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 597 - 609
  • [2] Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
    Alcolea, Daniel
    Pegueroles, Jordi
    Munoz, Laia
    Camacho, Valle
    Lopez-Mora, Diego
    Fernandez-Leon, Alejandro
    Le Bastard, Nathalie
    Huyck, Els
    Nadal, Alicia
    Olmedo, Veronica
    Sampedro, Frederic
    Montal, Victor
    Vilaplana, Eduard
    Clarimon, Jordi
    Blesa, Rafael
    Fortea, Juan
    Lleo, Alberto
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (09): : 1815 - 1824
  • [3] A practical guide to immunoassay method validation
    Andreasson, Ulf
    Perret-Liaudet, Armand
    van Doorn, Linda J. C. van Waalwijk
    Blennow, Kaj
    Chiasserini, Davide
    Engelborghs, Sebastiaan
    Fladby, Tormod
    Genc, Sermin
    Kruse, Niels
    Kuipenj, H. Bea
    Kulic, Luka
    Lewczuk, Piotr
    Mollenhauer, Brit
    Mroczko, Barbara
    Pametti, Lucille
    Vanmechelen, Eugeen
    Verbeek, Marcel M.
    Winblad, Bengt
    Zetterberg, Henrik
    Koel-Simmelink, Marleen
    Teunissen, Charlotte E.
    [J]. FRONTIERS IN NEUROLOGY, 2015, 6
  • [4] A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease
    Ashton, Nicholas J.
    Nevado-Holgado, Alejo J.
    Barber, Imelda S.
    Lynham, Steven
    Gupta, Veer
    Chatterjee, Pratishtha
    Goozee, Kathryn
    Hone, Eugene
    Pedrini, Steve
    Blennow, Kaj
    Scholl, Michael
    Zetterber, Henrik
    Ellis, Kathryn A.
    Bush, Ashley, I
    Rowe, Christopher C.
    Villemagne, Victor L.
    Ames, David
    Masters, Colin L.
    Aarsland, Dag
    Powell, John
    Lovestone, Simon
    Martins, Ralph
    Hye, Abdul
    [J]. SCIENCE ADVANCES, 2019, 5 (02)
  • [5] VAMP-2, SNAP-25A/B and syntaxin-1 in glutamatergic and GABAergic synapses of the rat cerebellar cortex
    Benagiano, Vincenzo
    Lorusso, Loredana
    Flace, Paolo
    Girolamo, Francesco
    Rizzi, Anna
    Bosco, Lorenzo
    Cagiano, Raffaele
    Nico, Beatrice
    Ribatti, Domenico
    Ambrosi, Glauco
    [J]. BMC NEUROSCIENCE, 2011, 12
  • [6] Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease
    Berchtold, Nicole C.
    Coleman, Paul D.
    Cribbs, David H.
    Rogers, Joseph
    Gillen, Daniel L.
    Cotman, Carl W.
    [J]. NEUROBIOLOGY OF AGING, 2013, 34 (06) : 1653 - 1661
  • [7] Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach
    Brinkmalm, Ann
    Brinkmalm, Gunnar
    Honer, William G.
    Moreno, Julie A.
    Jakobsson, Joel
    Mallucci, Giovanna R.
    Zetterberg, Henrik
    Blennow, Kaj
    Oehrfelt, Annika
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (10) : 2584 - 2592
  • [8] Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts
    Buckley, Rachel F.
    Mormino, Elizabeth C.
    Amariglio, Rebecca E.
    Properzi, Michael J.
    Rabin, Jennifer S.
    Lim, Yen Ying
    Papp, Kathryn V.
    Jacobs, Heidi I. L.
    Burnham, Samantha
    Hanseeuw, Bernard J.
    Dore, Vincent
    Dobson, Annette
    Masters, Colin L.
    Waller, Michael
    Rowe, Christopher C.
    Maruff, Paul
    Donohue, Michael C.
    Rentz, Dorene M.
    Kirn, Dylan
    Hedden, Trey
    Chhatwal, Jasmeer
    Schultz, Aaron P.
    Johnson, Keith A.
    Villemagne, Victor L.
    Sperling, Reisa A.
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (09) : 1193 - 1203
  • [9] Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration
    Cervantes Gonzalez, Alba
    Irwin, David J.
    Alcolea, Daniel
    McMillan, Corey T.
    Chen-Plotkin, Alice
    Wolk, David
    Sirisi, Sonia
    Dols-Icardo, Oriol
    Querol-Vilaseca, Marta
    Illan-Gala, Ignacio
    Angel Santos-Santos, Miguel
    Fortea, Juan
    Lee, Edward B.
    Trojanowski, John Q.
    Grossman, Murray
    Lleo, Alberto
    Belbin, Olivia
    [J]. MOLECULAR NEURODEGENERATION, 2022, 17 (01)
  • [10] Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging
    Chen, Ming-Kai
    Mecca, Adam P.
    Naganawa, Mika
    Finnema, Sjoerd J.
    Toyonaga, Takuya
    Lin, Shu-fei
    Najafzadeh, Soheila
    Ropchan, Jim
    Lu, Yihuan
    McDonald, Julia W.
    Michalak, Hannah R.
    Nabulsi, Nabeel B.
    Arnsten, Amy F. T.
    Huang, Yiyun
    Carson, Richard E.
    van Dyck, Christopher H.
    [J]. JAMA NEUROLOGY, 2018, 75 (10) : 1215 - 1224